

Cell Press Conflict of Interest Form

If submitting materials via Editorial Manager, please complete this form electronically and upload the file with your final submission.

Otherwise, please return the form as an email attachment to the copyeditor handling your manuscript.

Cell Press requires all authors to disclose any financial interest that might be construed to influence the results or interpretation of their manuscript.

As a guideline, any affiliation associated with a payment or financial benefit exceeding \$10,000 p.a. or 5% ownership of a company or research funding by a company with related interests would constitute a financial interest that must be declared. This policy applies to all submitted research manuscripts and review material.

Examples of statement language include: AUTHOR is an employee and shareholder of COMPANY; AUTHOR is a founder of COMPANY and a member of its scientific advisory board. This work was supported in part by a grant from COMPANY.

Please disclose any such interest below on behalf of all authors of this manuscript.

Please check one of the following:

None of the authors of this manuscript have a financial interest related to this work.

Please print the following disclosure statement in the Acknowledgments section:

X.D. is an employee and stockholder of NGM Biopharmaceuticals. The recombinant FGF21 was provided by Novo Nordisk.

Please provide the following information:

Please check this box to indicate that you have asked every author of this work to declare any conflicts of interest. Your answers on this form are on behalf of every author of this work.

Manuscript #: D-14-00119R2

Title: FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure and Weight Loss

Author list: Bryn M. Owen, Xunshan Ding, Donald A. Morgan, Katie Colbert Coate, Angie L. Bookout, Kamal Rahmouni, Steven A. Kliewer, David J. Mangelsdorf

Your name: Steven A. Kliewer

Date: 07/02/2014